SciLeads
SciLeads
Product Updates

BioPharma Updates 20th October, 2025

BioPharma Updates, October 20th, 2025.

SciLeads’ BioPharma is updated daily, giving our clients the most current insights on biopharma organizations, including Funding, Initial Public Offerings, Mergers & Acquisitions, Partnerships, and more. This week’s updates are below, with links to the organizations in the platform. If you don’t have BioPharma yet, start your free trial today.

Download this update:

View BioPharma updates as a PDF.
View BioPharma updates in an Excel (.XLS) format.

Funding

  • Kailera Therapeutics (MA, USA) raised $600M in Series B funding to advance its late-stage obesity pipeline, including global Phase 3 trials of KAI-9531, an injectable GLP-1/GIP dual agonist. 
  • Tubulis (Munich, Germany) raised $361M in Series C funding to expand clinical development of TUB-040, its lead antibody-drug conjugate for ovarian and lung cancers, and to advance additional ADC programs and platform technologies. 
  • Lila Sciences (MA, USA) raised $350M in Series A funding, bringing total capital to $550M, to expand its AI-driven “Science Factories” and commercialize its scientific superintelligence platform for life sciences, chemistry, and materials discovery. 
  • Kardigan (CA, USA) raised $254M in Series B funding to advance its late-stage portfolio of personalized cardiovascular medicines for dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis. 
  • Expedition Therapeutics (CA, USA) raised $165M in Series A funding to advance EXPD-101, a Phase 2–ready, once-daily oral DPP1 inhibitor for chronic obstructive pulmonary disease and other neutrophil-driven diseases. 
  • Arthrosi Therapeutics (CA, USA) raised $153M in Series E funding to complete pivotal Phase 3 development of pozdeutinurad (AR882) for the treatment of gout and tophaceous gout. 
  • Pelage Pharmaceuticals (CA, USA) raised $120M in Series B funding to advance PP405, a topical regenerative therapy that reactivates dormant hair follicle stem cells, into Phase 3 trials for androgenetic alopecia in 2026. 
  • Nilo Therapeutics (NY, USA) launched with $101M in Series A funding to develop a new class of medicines that harness neural circuits to restore immune balance in autoimmune and inflammatory diseases. 
  • TORL BioTherapeutics (CA, USA) raised $96M in Series C funding to advance clinical development of TORL-1-23, a Claudin 6–targeted antibody-drug conjugate for platinum-resistant ovarian and other CLDN6+ cancers. 
  • RealSense (CA, USA) spun out from Intel and raised $50M in Series A funding to scale its AI-powered vision technology and collaborate with NVIDIA to advance perception systems for humanoid and autonomous mobile robots. 
  • Kernal Bio (MA, USA) received up to $48M from ARPA-H to advance its in vivo mRNA-encoded CAR T-cell therapy program KR-402 for hematological cancers and autoimmune diseases. 
  • Tessera Therapeutics (MA, USA) received up to $41.3M from ARPA-H to develop single-dose in vivo CAR-T therapies using its Gene Writing™ and lipid nanoparticle delivery platforms for cancer and autoimmune diseases. 
  • Step Pharma (Saint-Genis-Pouilly, France) raised $41M in Series C funding to advance clinical development of dencatistat, a first-in-class CTPS1 inhibitor being tested for lymphoma, solid tumors, and essential thrombocythaemia. 
  • BioNTech (Kigali, Rwanda) received a $40M grant to expand its mRNA vaccine manufacturing facility producing vaccines for diseases including malaria, tuberculosis, HIV, and mpox. 
  • Jupiter Endovascular (CA, USA) raised over $40M in Series B funding to complete its SPIRARE II pivotal trial, prepare for commercialization, and expand clinical applications of its Transforming Fixation (TFX) platform. 
  • Affinia Therapeutics (MA, USA) raised $40M in Series C funding to advance AFTX-201, a gene therapy for BAG3 dilated cardiomyopathy, and support its broader cardiovascular and neurological gene therapy pipeline. 
  • ABK Biomedical (Halifax, Canada) raised $35M in Series D funding to support clinical operations, commercialization of Eye90 microspheres®, and continued product development in interventional oncology. 
  • Omnix Medical (Jerusalem, Israel) raised $25M in Series C funding to complete Phase II proof-of-concept studies of OMN6, a first-in-class antimicrobial peptide for treating multidrug-resistant Gram-negative infections, and to advance its broader anti-infective pipeline. 
  • AeroRx Therapeutics (CA, USA) raised $21M in Series A funding to advance AERO-007, a once-daily nebulized LABA/LAMA therapy for chronic obstructive pulmonary disease, into late-stage clinical development. 
  • Mission Therapeutics (Cambridge, United Kingdom) raised $13.3M in funding to fund a Phase 1b proof-of-mechanism clinical trial of MTX325, a first-in-class, potentially disease-modifying treatment for Parkinson’s disease. 
  • Ascribe Bio (NY, USA) raised $12M in Series A funding to launch Phytalix®, a next-generation biofungicide providing sustainable and affordable disease control for global agriculture. 
  • 4D Molecular Therapeutics (CA, USA) received up to $11M in additional funding from the Cystic Fibrosis Foundation to advance 4D-710, a genetic therapy for cystic fibrosis lung disease, into Phase 2 clinical development. 
  • EVerZom (Strasbourg, France) raised $10.8M in funding to initiate clinical development of EVerGel™, an exosome-based therapy for Crohn’s perianal fistula, and to scale its GMP exosome biomanufacturing platform. 
  • VitriVax (CO, USA) received a $9.9M Gates Foundation grant to scale up GMP manufacturing for its ALTA® vaccine formulation technology and prepare for Phase 1 clinical trials. 
  • Amplifi Vascular (MO, USA) raised $6.9M in Series A funding to advance its Vein Dilation System, designed to improve arteriovenous fistula creation and maturation for hemodialysis patients. 
  • Kneu Health (London, United Kingdom) raised $5.6M in seed funding to scale its FDA-cleared smartphone platform for continuous monitoring and early detection of neurological decline in Parkinson’s and dementia patients.
  • VeraMorph (MA, USA) received a $5M SBIR Fast Track grant from the National Cancer Institute to advance development of the first effective oral fulvestrant therapy for estrogen receptor–positive metastatic breast cancer. 
  • Neuronoff (OH, USA) raised $4.5M in funding to advance its minimally invasive Injectrode® platform toward FDA clearance and commercial launch for the treatment of chronic pain. 
  • Daré Bioscience (CA, USA) received a $4M grant installment, bringing total funding to $41.8M of a $49M commitment, to advance its smart drug delivery device DARE-LARC1 for long-acting contraception. 
  • EVOQ Therapeutics (MI, USA) received a $2M NIH grant to advance development of its NanoDisc-based therapy for celiac disease, aiming to reeducate the immune system and restore immune tolerance. 
  • DemeRx (FL, USA) received a $1.7M NIH SBIR grant to advance DMX-1001, a neuroplastogen drug candidate for treating alcohol use disorder through a novel mechanism that promotes neuroplasticity and reduces relapse risk. 
  • Confo Therapeutics (Ghent, Belgium) received a $1.1M VLAIO grant to develop ultra-long-acting antibody-based GPCR therapeutics for metabolic and endocrine disorders, including obesity.
  • HistoSonics (MI, USA) raised $250M in oversubscribed growth financing to support the commercial expansion of its Edison® histotripsy platform and advanced clinical programs.
  • Veradermics (UT, USA) raised $150M in oversubscribed Series C financing to advance VDPHL01 through multiple Phase 3 trials as a potential first non-hormonal oral therapeutic for hair regrowth in women and men.
  • Adcytherix (Paris, France) raised $114M in Series A financing to accelerate its antibody-drug conjugate pipeline with a strategic focus on novel payloads.
  • Peptilogics (PA, USA) raised $78M to advance its lead peptide therapeutic, zaloganan, into a pivotal trial targeting serious infections.
  • BridGene Biosciences (CA, USA) raised $28M in Series B financing to accelerate clinical development of its oncology candidate BGC-515 and expand its IMTAC™ platform.
  • Monod Bio (WA, USA) received a $750K Grand Challenges grant to develop a rapid, AI-designed protein-based diagnostic for preeclampsia to improve maternal health in low-resource settings.
  • TruDiagnostic (KY, USA) received an NIH Small Business Innovation Research (SBIR) grant to advance its W-Function Epigenomic Roadmap, a next-generation diagnostic model that tracks dynamic DNA methylation changes to improve prediction and prevention of chronic diseases such as cardiovascular disease and type 2 diabetes.
  • Aphios Corporation (MA, USA) received an NIH SBIR Phase I grant to advance development of Zindol®, a ginger-derived botanical drug for treating chemotherapy-induced nausea and vomiting.
  • Aarvik Therapeutics (CA, USA) raised an undisclosed amount in a Series Seed 2 round, including investment from Laurus Labs, to advance its pipeline of next-generation antibody-drug conjugates developed using its MUTTA™ platform. 
  • Cytiva (MA, USA) received ARPA-H funding to develop an in vivo CAR-T therapy platform for gastrointestinal cancers, aiming to target solid tumors and reduce manufacturing costs by tenfold. 

Emerging

  • Excellergy (CA, USA) launched with $70M in Series A financing to advance its portfolio of first-in-class Effector Cell Response Inhibitors (ECRIs) — a new class of trifunctional biologics designed to rapidly remove receptor-bound IgE, neutralize free IgE, and downregulate FceRI expression for complete allergic control. 
  • ImmunoVec (CA, USA) emerged from stealth with up to $40.7M in ARPA-H EMBODY funding to advance its in vivo cell engineering platform and develop a first-in-class DNA-loaded nanoparticle therapy for autoimmune diseases. 
  • Liberate Bio (MA, USA) emerged from stealth with $31M in seed funding to advance its RNA barcoding platform and develop in vivo CAR-M therapies targeting macrophages and monocytes, with first clinical trials planned for 2026. 
  • Eldian Biomed (Bern, Switzerland) received $43,000 to advance CloudLi, an injectable microcushion therapy for osteoarthritis that targets inflammation and cartilage wear.
  • NanoZymeX (Basel, Switzerland) received $43,000 to develop a lipid nanoparticle platform for targeted enzyme delivery to treat lysosomal storage diseases, starting with Pompe disease.
  • Rare Therapeutics (PA, USA) launched to develop and deliver gene therapies for ultra-orphan diseases, starting with programs targeting GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy. 

Post IPO Equity

  • Praxis Precision Medicines, Inc. (MA, USA) announced a $525M underwritten public offering of common stock and pre-funded warrants to support continued development of its CNS disorder therapies targeting neuronal excitation-inhibition imbalance.
  • Apogee Therapeutics (MA, USA) announced a $300M underwritten public offering of common stock and pre-funded warrants to support advancement of its inflammatory and immunology biologics pipeline.
  • Spyre Therapeutics (MA, USA) announced a $275M underwritten public offering of common stock to support advancement of its antibody-based therapies for inflammatory bowel disease and other immune-mediated conditions.
  • EyePoint Pharmaceuticals (MA, USA) announced a $150M underwritten public offering of common stock and pre-funded warrants to advance clinical development of DURAVYU™ for wet AMD and DME, support earlier-stage pipeline programs, and for general corporate purposes.
  • Lexeo Therapeutics (NY, USA) announced a $135M underwritten public offering and concurrent private placement of common stock and pre-funded warrants to advance its genetic medicine programs for cardiovascular diseases.
  • atai Life Sciences (Berlin, Germany) announced a $130M underwritten public offering of common shares to advance clinical development of its psychedelic-based therapies for treatment-resistant depression and other mental health disorders.
  • C4 Therapeutics (MA, USA) announced a $125M underwritten public offering of common stock, pre-funded warrants, and accompanying warrants to advance clinical development of cemsidomide for multiple myeloma.
  • Propanc Biopharma, Inc. (Australia) announced a strategic financing agreement of ~$100M with Hexstone Capital LLC to accelerate clinical pipeline development and establish a $100M Digital Asset Treasury within 12 months.
  • Idorsia Pharmaceuticals Ltd (Switzerland) announced an $81.4M accelerated bookbuilt offering of 16.4M new and treasury shares to strengthen its balance sheet and support commercialization of QUVIVIQ and pipeline advancement.
  • Rani Therapeutics (CA, USA) announced a $60.3M private placement to support the advancement of its RaniPill® oral biologics platform and extending cash runway into 2028.
  • ADC Therapeutics (Lausanne, Switzerland) announced a $60M PIPE financing to support the commercial expansion of ZYNLONTA and strengthen the balance sheet.
  • Adagio Medical Inc. (CA, USA) announced a $19M private placement of common stock and warrants to support clinical and product development and for general corporate purposes.
  • Quoin Pharmaceuticals (VA, USA) announced a $16.5M private placement to support clinical development of QRX003 for Netherton Syndrome and general corporate purposes.
  • Cardiol Therapeutics (Oakville, Canada) announced an $11M private placement of units to fund its Phase III MAVERIC trial of CardiolRx™ for recurrent pericarditis, advance its next-generation heart failure therapy CRD-38, and support operations into 2027.
  • Sharp Therapeutics (PA, USA) announced a $10M non-brokered private placement of common shares to support Phase I trials of its oral Gaucher disease candidate ‘901 and for working capital purposes.
  • VolitionRx (NV, USA) announced a $6M underwritten public offering of common stock and warrants, with proceeds to support research, product development, clinical studies, commercialization, and potential strategic acquisitions.
  • Conexeu Sciences Inc. (Vancouver, Canada) announced a $5M Regulation Crowdfunding (Reg CF) financing to accelerate development and commercialization of its patented collagen platform for wound care, medical aesthetics, and tissue engineering applications.
  • ENDRA Life Sciences (MI, USA) announced a $4.9M private placement to fund its new digital asset treasury strategy and support completion of its TAEUS pilot validation imaging study for MASLD/MASH.
  • Bluejay Diagnostics, Inc. (MA, USA) announced a $4.5M private placement of common stock and warrants to support FDA approval efforts, clinical studies, R&D activities, and general working capital.
  • Xenetic Biosciences (MA, USA) announced a $4.5M underwritten public offering of common stock to support working capital and general corporate purposes.
  • Theriva Biologics (MD, USA) announced a $4M warrant inducement agreement with existing institutional investors for the immediate exercise of warrants at $0.54 per share, with proceeds supporting working capital and general corporate purposes.
  • AB Science (Paris, France) announced a $3M private placement of shares and attached warrants to support ongoing operations and advance clinical development of AB8939 in acute myeloid leukemia, including completion of Phase 1 combination therapy and initiation of an expansion study.
  • Solvonis Therapeutics (London, United Kingdom) announced a ~$1.6M direct subscription of ordinary shares to expand its CNS R&D programs across addiction, psychiatry, and neurology.
  • Maia Biotechnology, Inc. (IL, USA) announced a $736.6K private placement of common stock and warrants to support execution of Step 1 of Part C of its Phase II THIO-101 trial and for working capital.

Post IPO Debt

  • Candel Therapeutics (MA, USA) announced a $130M term loan facility to fund its Phase 3 trial of CAN-2409 in NSCLC and advance preparations for a potential prostate cancer launch.
  • Karyopharm Therapeutics (MA, USA) announced a $100M financing package comprising new term loans, convertible note exchanges, and an $8.75M private placement of common stock and warrants to strengthen its balance sheet, extend cash runway into 2Q26, and support its Phase 3 SENTRY trial in myelofibrosis.

Mergers and Acquisitions

  • Novo Nordisk (Bagsværd, Denmark) to acquire Akero Therapeutics (CA, USA) for $6.3B to expand its MASH portfolio. This deal will add Akero’s promising phase 3 FGF21 analogue to Novo Nordisk’s pipeline, strengthening its position in metabolic and liver disease treatment.
  • Boston Scientific (MA, USA) to acquire Nalu Medical (CA, USA) for $1.7B. This deal will expand Boston Scientific’s neuromodulation portfolio and strengthen its position in treating chronic pain through advanced implantable neurostimulation technologies.
  • Pure Health (Abu Dhabi, United Arab Emirates) to acquire Hellenic Healthcare Group (Athens, Greece) for $870M to strengthen its global healthcare platform. This acquisition expands PureHealth’s international footprint and enhances its presence in the European healthcare market.
  • BioCryst Pharmaceuticals (NC, USA) to acquire Astria Therapeutics (MA, USA) for $648M to strengthen its presence in hereditary angioedema (HAE). This deal aims to expand BioCryst’s HAE portfolio and transform its long-term growth profile.
  • TransCode Therapeutics (MA, USA) to acquire Polynoma (CA, USA) for $25M to form a first-in-class immuno-oncology and metastatic prevention company. This deal, backed by a subsidiary of CK Life Sciences, aims to advance innovative cancer therapies and expand TransCode’s oncology portfolio.
  • Peli BioThermal (MN, USA) to acquire Cold Chain Technologies (MA, USA) to expand cold chain logistics solutions and advance cryogenic cell and gene therapy transport. This acquisition strengthens Peli BioThermal’s position in temperature-controlled packaging for the life sciences sector.
  • CytoMed Therapeutics (Singapore) to acquire relevant assets of TC BioPharm (Edinburgh, United Kingdom) to expand its cell therapy capabilities. This deal aims to strengthen CytoMed’s pipeline and enhance its presence in the global cell and gene therapy market.
  • Viatris (PA, USA) to acquire Aculys Pharma (Tokyo, Japan). This acquisition includes exclusive rights to Pitolisant in Japan and Spydia in Japan and other Asia-Pacific markets. This deal strengthens Viatris’ presence in the central nervous system and sleep disorder therapeutic areas across the region.
  • Merck (NJ, USA) to acquire the chromatography business of JSR Life Sciences (Tokyo, Japan). This acquisition expands Merck’s Protein A capabilities and strengthens its downstream bioprocessing portfolio.
  • Quintara Biosciences (CA, USA) to acquire the Sanger sequencing business of Laragen (CA, USA). This deal strengthens service continuity and supports Quintara’s strategic expansion in Los Angeles.
  • OSR Holdings (Seoul, South Korea) to acquire Woori IO (Seoul, South Korea). This acquisition aims to advance noninvasive glucose monitoring technologies and transform diabetes care.
  • Novo Nordisk (Bagsværd, Denmark) to acquire clinical-stage MASP-3 inhibitor Zaltenibart (OMS906) assets from Omeros (WA, USA). This asset purchase and license agreement expands Novo Nordisk’s pipeline in complement-mediated disease therapies.
  • Precision BioLogic (Dartmouth, Canada) to acquire George King Bio-Medical (KS, USA). This deal is intended to expand Precision BioLogic’s presence in the global hemostasis diagnostics market and strengthen its portfolio of quality control plasma products.
  • XORTX Therapeutics (Calgary, Canada) to acquire the renal anti-fibrotic therapeutic program from Vectus Biosystems (Sydney, Australia). This acquisition will enhance XORTX’s pipeline in kidney disease treatments and support its strategic focus on innovative therapies for progressive renal disorders.

Partnerships

  • Kite Pharma (CA, USA), a Gilead company, and Pregene Biopharma Co., Ltd. (Guangdong, China) announced a ~$1.64B collaboration to co-develop next-generation in vivo CAR-T therapies targeting oncology, autoimmune, and other diseases.
  • Roche (Switzerland) and Hansoh Pharma (China) announced a $1.53B global licensing agreement granting Roche worldwide rights outside Greater China to HS-20110, a CDH17-targeting antibody-drug conjugate in Phase I development for colorectal and other solid tumors.
  • Rani Therapeutics (CA, USA) and Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan) announced a ~$1.1B collaboration and license agreement to develop and commercialize an oral antibody therapy using Rani’s RaniPill® platform for rare diseases
  • Dianthus Therapeutics (MA, USA) and Leads Biolabs (Nanjing, China) announced a ~$1B exclusive license agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor for autoimmune diseases including lupus.
  • Nabla Bio (MA, USA) and Takeda Pharmaceuticals (Tokyo, Japan) announced a ~$1B AI-driven collaboration applying Nabla’s JAM platform for de novo antibody and multispecific design across early programs.
  • Boehringer Ingelheim (Germany) and Aimed Bio Inc. (Seoul, South Korea) announced a ~$991M global collaboration and license agreement to develop a novel exatecan-based antibody-drug conjugate targeting a tumor-selective marker across multiple cancers, with first-in-human studies expected in 2026.
  • EVOQ Therapeutics (IL, USA) and Sanofi (France) announced a ~$500M collaboration to develop NanoDisc-based therapies aimed at restoring immune tolerance in autoimmune diseases.
  • AviadoBio (London, United Kingdom) and UgeneX Therapeutics (Shanghai, China) entered a ~$413M exclusive option and license deal for UGX-202, an AAV-based optogenetic gene therapy for retinitis pigmentosa.
  • SystImmune (WA, USA) received a $250M milestone payment from Bristol Myers Squibb (NJ, USA) after dosing the first patient in a Ph2/3 trial of iza-bren, a bispecific EGFR/HER3 ADC for TNBC.
  • Samsung C&T and Samsung Electronics (South Korea) announced a $110M investment and partnership with GRAIL (CA, USA) to launch the Galleri® multi-cancer early detection test in South Korea, with potential expansion to Japan and Singapore.
  • insitro (CA, USA) and Bristol Myers Squibb (NJ, USA) extended their ALS collaboration for one year with up to $20M, leveraging insitro’s ChemML™ AI platform for novel therapies.
  • Turbine (Budapest, Hungary) announced a collaboration with AstraZeneca (Cambridge, United Kingdom) to use its AI-powered Simulated Cell™ platform to accelerate ADC discovery and reduce experimental screening needs.
  • Alpenglow Biosciences (WA, USA) and Virdx (MA, USA) announced a multi-year collaboration to develop AI-enabled prostate cancer diagnostics combining 3D pathology and MRI-based biophysics models.
  • iQure Pharma Inc. (NJ, USA) and the University of Padova (Italy) partnered to study the mechanism of iQ-007, an EAAT2-targeted therapy restoring glutamate balance in CNS disorders.
  • Akadeum Life Sciences, Inc. (MI, USA) and BioIVT (NY, USA) are collaborating to improve T cell quality for cell therapy using Akadeum’s microbubble isolation and BioIVT’s LEUKOMAX™ leukopaks.
  • CalciMedica (CA, USA) and Telperian Inc (CA, USA) announced partnership  to apply Telperian’s AI-driven analytics to clinical data for Auxora™, supporting pivotal trial design in acute pancreatitis.
  • Synaptive Medical (Toronto, Canada) and Centile Bioscience (London, United Kingdom) announced a partnership to integrate Centile’s AI brain analytics into Modus Plan™, enhancing precision in neurosurgical planning.
  • Symrise AG (Germany) and Aplantex (Montreal, Canada) partnered to co-develop plant-based bioactives via Aplantex’s green biotech platform, following validation of key antioxidant compounds.
  • Stereotaxis (MO, USA) and CardioFocus (MA, USA) partnered to advance the first robotic pulsed field ablation (PFA) system for cardiac arrhythmias, combining Centauri PFA with the MAGiC catheter.
  • Landmark Bio (MA, USA) and Mass General Brigham (MA, USA) announced a collaboration to advance early-stage cell and gene therapies, with Landmark Bio providing development and manufacturing support through the Mass General Brigham Gene and Cell Therapy Institute.
  • Jacobio Pharma (Beijing, China) announced a strategic partnership  with Oceanpine Capital (Beijing, China) to advance its oncology pipeline and accelerate R&D growth.
  • Techsomed (Rehovot, Israel) and Medtronic (MN, USA) announced a collaboration integrating Techsomed’s AI-powered BioTraceIO360™ software with Medtronic’s Emprint™ microwave ablation system to enhance image-guided ablation therapy through real-time visualization, predictive margin control, and dynamic treatment planning.
  • Citius Oncology, Inc. (NJ, USA) and EVERSANA (IL, USA) announced an exclusive agreement to support the U.S. launch of LYMPHIR™ for relapsed or refractory cutaneous T-cell lymphoma in Q4 2025.
  • Tempus AI (IL, USA) and Whitehawk Therapeutics (NJ, USA) announced a multi-year collaboration to use Tempus’ AI-driven real-world data to optimize biomarker research and clinical development for Whitehawk’s antibody-drug conjugate (ADC) cancer programs.
  • RetinalGenix Technologies, Inc. (FL, USA) and Seer (CA, USA) announced a collaboration to integrate ultra-high-resolution retinal imaging with advanced proteomic profiling to identify biomarkers for early detection and monitoring of neurodegenerative, retinal, and systemic diseases.
  • Taiho Pharmaceutical (Japan) exercised its option under a 2017 agreement with Arcus Biosciences (CA, USA) to develop and commercialize casdatifan (AB521), a HIF-2α inhibitor for clear cell renal cell carcinoma, in Japan and parts of Asia.

Registered Direct Offering (RDO)

  • Adicet Bio, Inc (CA, USA) announced an $80M underwritten registered direct offering of common stock and pre-funded warrants to support advancement of its allogeneic gamma delta T cell therapy programs for autoimmune diseases and cancer.
  • Humacyte (NC, USA) announced a $60M registered direct offering of common stock and warrants, with proceeds supporting the company’s commercial-stage platform developing universally implantable, bioengineered human tissues.
  • Annovis Bio, Inc. (PA, USA) announced a $6M registered direct offering of common stock and pre-funded warrants to support working capital and general corporate purposes.
  • Envoy Medical (MN, USA) announced a $4M registered direct offering of common stock to support working capital and general corporate purposes.
  • Akari Therapeutics, Plc (London, United Kingdom) announced a $2.5M registered direct offering of ADSs and concurrent private placement of Series E and F warrants to support working capital and R&D of its novel ADC payload program.
  • bioAffinity Technologies (TX, USA) announced a $1.8M registered direct offering to support growing sales of its CyPath® Lung noninvasive lung cancer test and for general corporate purposes. WallachBeth Capital acted as sole placement agent.

Closures and Layoffs

  • Kezar Life Sciences (CA, USA) to lay off 41 employees after the FDA canceled a key meeting to discuss the next trial for its lupus nephritis treatment, prompting the company to scale back operations and preserve resources.

Is there anything else you’d love to see here or have added to the platform? Please don’t hesitate to contact us with your feedback.